Abstract:Abstract Purpose Our aim was to characterize the newly established new drug conditional approval process in China and discuss the challenges and opportunities with respect to new drug research and development and registration. Methods We examined the new approval program through literature review, law analysis, and data analysis. Data were derived from published materials, such as journal articles, government publications, press releases, and news articles, along with statistical data from INSIGHT-China Pharma Databases, the China Food and Drug Administration website, the Center for Drug Evaluation website, the US Food and Drug Administration website, and search results published by Google. Findings Currently, there is a large backlog of New Drug Applications in China, mainly because of the prolonged review time at the China Food and Drug Administration, resulting in a lag in drug approvals. In 2015, the Chinese government implemented the drug review and registration system reform and tackled this issue through various approaches, such as setting up a drug review fee system, adjusting the drug registration classification, and establishing innovative review pathways, including the conditional approval process. Implications In Europe and the United States, programs comparable to the conditional approval program in China have been well developed. The conditional approval program recently established in China is an expedited new drug approval process that is expected to affect new drug development at home and abroad and profoundly influence the public health and the pharmaceutical industry in China. Like any program in its initial stage, the conditional approval program is facing several challenges, including setting up a robust system, formatting new drug clinical research requirements, and improving the regulatory agency’s function for drug review and approval. The program is expected to evolve and improve as part of the government mandate of the drug registration system reform.

Evaluation on New Drug Registration System in America and Its Illumination for China

New Problems in FDA Problems in Drug Registration

Simulation Effect of the Implementation of Drug Registration Regulation (2007 Edition) on Innovatory Drug Research and Development in China

Research on Approval and Regulatory System of Generics in USA

Overview of Drug Evaluation System in China

Comparisons on New Drug Technical Review Between SFDA and FDA

The New Drug Conditional Approval Process in China: Challenges and Opportunities

Comparison of Marketing Authorization System for Drug Wholesale Enterprises between China and America

On the Amendments of China’s Provisions for Drug Registration

Performance appraisal system of new drug review in Japan and its reference to China

Study on the positive effects of data protection system on the availability of innovative drug--based on a comparative analysis of keppra marketing between China and America

Preliminary Analysis of Drug Registration Management in EU

Research on priority review of new drugs in China

Analysis and Comparison of Foreign and Domestic Orphan Drug Registration Policies

Review of Japanese Charge Standard for Drug Registration and Its Enlightenment to the Improvement of Corresponding Charge System in China

Study on the combined utilization of new drug expedited programs in America: the empirical analysis of osimertinib's R&D and application process

Disscuss on New Drug Research and Development after Amending the Drugs Registration Policing Method

Introduction of the American Examination and Approval Policies for Pediatric Drugs

Enlightenment of US Drug Regulation System for Our Nation

Recent Advances in Drug Development and Regulatory Science in China

Research on the link between expedited review and drug reevaluation from the perspective of innovation incentive based on American experience